metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Probiotics: a possible role in treatment of adult and pediatric non alcoholic fa...
Información de la revista
Vol. 12. Núm. 1.
Páginas 161-163 (enero - febrero 2013)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 12. Núm. 1.
Páginas 161-163 (enero - febrero 2013)
Open Access
Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease
Visitas
1127
Pietro Vajro
,
Autor para correspondencia
pvajro@unisa.it

Correspondence and reprint request:
, Claudia Mandato**, Claudio Veropalumbo***, Ida De Micco***
* Chair of Pediatrics, University of Salerno, Salerno, Italy
** Pediatric Hospital “Santobono”, Naples, Italy
*** Department of Pediatrics, University of Naples “Federico II”, Naples, Italy
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Probiotics treatment studies in adults and in children with NAFLD
Texto completo

Dear Editor:

Sir, we read with much interest the Concise Review by Doctors Machado and Cortez-Pinto on gut microbiota and nonalcoholic fatty liver disease (NAFLD) appearing in the July-August issue of Annals of Hepatology.1 The Authors correctly pointed out that, based on preliminary experiments on different NAFLD animal models and different bacterial strains of probiotics, it would be expected that interventions which modulate intestinal microbiota may be beneficial also in human obesity related liver dysfunction. In this regard they mentioned the two non-randomized pilot studies2,3 quoted by the Cochrane meta-analysis of Lirussi, et al.4 as the only meager evidence available at present.

We would suggest to consider that results of the first one,2 however, are strongly puzzled by co-treatment with prebiotics and antioxidants, i.e. two other alleged components of NAFLD therapeutic arsenal.5 The second study,3 instead, investigated the outcome of liver dysfunction parameters and oxidative stress markers using probiotics as the single treatment in different categories of adult chronic liver disease including only a subgroup of NAFLD patients for whom liver function tests data were not shown.

Here we recommend, therefore, to contemplate also two other recent pilot, double blind, randomized clinical trials6,7 which appeared subsequent to 2007 meta-analysis by Lirussi. These studies compare in table 1.

Table 1.

Probiotics treatment studies in adults and in children with NAFLD

Authors (reference)  Loguercio, et al.2  Loguercio, et al.3  Aller, et αl.6  Vajro, et al.7 
Year of publication  2002  2005  2011  2011 
Type of study  Open label.  Open label  Double blind RCT  Double blind RCT 
Number patients/disease  10/NASH.  22/NAFLD  30/NAFLD  20/NAFLD 
Mean age (years)  37 (range 29–56)  37 (range 29–56) 44.3 ± 15.1 placebo group.  49.4 ± 10.9 treated group.  10.7 ± 2.1 
Treatment  Different bacteria strain, prebiotic, antioxidants.*  VSL#3  Lactobacillus bulgaricus and Streptococcus thermophilus 500 millions CFU  Lactobacillus GG 
Primary end-point  Aminotransferase and GGT variation, cytokines, lipid peroxidation markers.  Aminotransferase and GGT variation, cytokines, lipid peroxidation markers (MDA, 4-HNE), nitrosothiols (S-NO).  Aminotransferase and GGT variation, cytokines (TNF α, IL6).  ALT and GGT variation, liver echogenicity, TNF α values, H2BT, PG- PS IgA, hepatorenal-US ratio. 
Results  ΔALT-64.5 ± 26.5%; Δ GGT-55.2 ± 31.3% (p < 0.01 vs. basal values). Decreased lipid peroxidation (significant value, not shown)  AST; ALT; GGT: data not shown for NAFLD patients. Significant ion reduction (p < 0.01) of MDA, 4-HNE, and S-NO.  Decrease in probiotic treated group of ALT: 67.7 ± 25.1 to 60.4 ± 30.4 (p < 0.05); AST 41.3 ± 15.5 to 35.6 ± 10.4 (p < 0.05); GGT: 118.2 ±63.1 to 107.7 ± 60.8 (p<0.05). Unchanged in placebo group. Cytokines unchanged.  ΔALT and PG-PS IgA treated vs. control p < 0.03 for both. ALT normalization 8/10 cases in treated vs. 3/7 in placebo. 
Length of treatment  2 months.  3 months.  3 months.  2 months 
Diet regimen  Not supervised.  Not supervised.  Dietary record before and after treatment.  Changes not encouraged. 
Anthropometric parameters  Not supervised.  Not supervised.  Weight, BMI, waist to hip circumference, fat mass: all unchanged.  BMI Ζ score, US visceral fat, weight, height, waist: all unchanged. 
*

Lactobacillus acidophilus, Bifidus, Rhamnosus, Plantarum, Salivarius, Bulgaricus, Lactis, Casei, Breve, + FOS Fructo-oligosaccharides as prebiotic + vitamins B6, B2, B12, D3, and C + folic acid, Zn oxide, Fe gluconate and Κ iodure. ALT: alanine aminotransferase U/l. AST: aspartate aminotransferase U/l. BMI: body mass index. GGT: gamma glutamyl-transpeptidase U/l. 4-HNE: 4-hydroxynomenal. H28T: hydrogen breath test. MDA: malondialdheyde. NAFLD: non alcoholic fatty liver disease. NASH: non alcoholic steato-hepatitis. PG-PS: peptidoglycan-polysaccharide. RCT: randomized clinical trial. TNF: tumor necrosis factor. US: ultrasonography.

The first RCT6 evaluated the effects of a 12 week course treatment with 500 million of Lactobacillus bulgaricus and Streptococcus thermophiles/day in adult patients with biopsy proven NAFLD. Even though anthropometric parameters and cardiovascular risk factors remained unchanged in both treated and control groups, probiotic treatment resulted in a significant improvement of aminotrans-ferases levels.

The second RCT7 was carried out by our group in obese children with NAFLD unable to comply with lifestyle interventions. We showed that a short (8 weeks) course of probiotic treatment with Lactobacillus GG (12 billion CFU/day), irrespective of changes in BMI z score and visceral fat, determined a significant decrease (with normalization in 80% of cases) in alanine aminotransferase values. This was associated also to a significant reduction of anti peptidoglycan-polysaccharide antibodies (i.e. an alleged small intestinal bacterial overgrowth marker), while tumor necrosis factor-α, and ultrasonographic bright liver parameters remained fairly stable.

Although several aspects of probiotics beneficial action in NAFLD (e.g. type of strain and doses) still need further elucidation, altogether, these other data confirm and strengthen Doctors Machado and Cortez-Pinto preliminary conclusions.1 That is, intestinal flora manipulation warrants consideration as a therapeutic tool to treat obesity related liver dysfunction of adult and pediatric individuals who are noncompliant to its difficult mainstay treatment, i.e. weight loss through slimming diets and lifestyle interventions.5,7

As even minimal weight and lifestyle changes may affect the biochemical and imaging parameters of NAFLD,8 we suggest that future probiotics studies –regardless of an existing controlled harm– should still be designed as short-term trials, strictly registering patients’ anthropometric changes. This precaution will help to circumvent the unpredictable effects of lifestyle changes that have hitherto usually confounded the results of a number of long-term studies with this and other treatments in the challenging obese patients population.5

References
[1.]
Machado M.V., Cortez-Pinto H..
Gut microbiota and nonalcoholic fatty liver disease.
Ann Hepatol, 11 (2012), pp. 440-449
[2.]
Loguercio C., De Simone T., Federico A., Terracciano F., Tuccillo C., Di Chicco M., Carteni M..
Gut-liver axis: a new point of attack to treat chronic liver damage?.
Am J Gastroenterol, 97 (2002), pp. 2144-2146
[3.]
Loguercio C., Federico A., Tuccillo C., Terracciano F., D’Auria M.V., De Simone C., Del Vecchio Blanco C..
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.
J Clin Gastroenterol, 39 (2005), pp. 540-543
[4.]
Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis, Cochrane Database Syst Rev 2007; CD005165
[5.]
Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H..
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
J Pediatr Gastroenterol Nutr, 48 (2009), pp. 587-596
[6.]
Aller R., De Luis D.A., Izaola O., Conde R., Gonzalez Sagrado M., Primo D., et al.
Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.
Eur Rev Med Pharmacol Sci, 15 (2011), pp. 1090-1095
[7.]
Vajro P., Mandato C., Licenziati M.R., Franzese A., Vitale D.F., Lenta S., Caropreso M., et al.
Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease.
J Pediatr Gastroenterol Nutr, 52 (2011), pp. 740-743
[8.]
Vajro P., Fontanella A., Perna C., Orso G., Tedesco M., De Vincenzo A..
Persistent hyperaminotransferasemia resolving after weight reduction in obese children.
J Pediatr, 125 (1994), pp. 239-241
Copyright © 2013. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos